Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.

Carfilzomib, the next generation of proteasome inhibitor, may increase osteoblast-related markers in patients with multiple myeloma, but the molecular mechanism of its effect on mesenchymal stem cell differentiation to osteoblasts remains unknown. Herein, we demonstrated that carfilzomib significant...

Full description

Bibliographic Details
Main Authors: Bo Hu, Yu Chen, Saad Z Usmani, Shiqiao Ye, Wei Qiang, Xenofon Papanikolaou, Christoph J Heuck, Shmuel Yaccoby, Bart O Williams, Frits Van Rhee, Bart Barlogie, Joshua Epstein, Ya-Wei Qiang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3774816?pdf=render

Internet

http://europepmc.org/articles/PMC3774816?pdf=render

Similar Items